Mesoblast

What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

Company

Indicator

Code Company Date Close Change Indicator Value Signal

Trading Performance

Fibonacci Retracements

Score

0.3

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 13 28.9 0.38% 0.63% 14.6% -6.4% 21.7%
SHORT 14 24.1 0.36% 0.56% 10.1% -4.7% 8.1%

Summary

Technical Analysis

Mesoblast (MSB.AX)


Indicator:

FIBONACCI RETRACTION


Signal Strength: MEDIUM
Recommendation:

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading position.


Mesoblast (ASX:MSB) : The current Fibonacci Retraction levels are:
(23.61%) $1.71
(38.2%) $1.75
(50%) $1.79
(61.8%) $1.83

The current support levels are:
(78.6%) $1.88
(100%) $1.94
(138.2%) $2.05
(161.8%) $2.13
(261.8%) $2.43
(423.61%) $2.91



A Fibonacci retracement is a term used in technical analysis that refers to areas of support (price stops going lower) or resistance (price stops going higher). Fibonacci retracement levels use horizontal lines to indicate areas of support or resistance at the key Fibonacci levels before the trend continues in the original direction.

Calculation: Fibonacci Retracements:
1) Uptrend: C = B — (B — A) x N%;
2) Downtrend: C = B + (A — B) x N%;
3) Fibonacci Levels:
a) 23.61%;
b) 38.2%;
c) 50%;
d) 61.8%;
e) 78.6%;
f) 100%,


PROFILE: Mesoblast (MSB.AX)


Stock Exchange: ASX
Company: Mesoblast
Ticker Codes: | MSB.AX | ASX:MSB |

About Mesoblast (ASX:MSB):

Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.

Top 10:

Fibonacci Retracements

Download
Company Close Change(%) Volume Value Signal
MDC Mcconnell Dowell Corporation 0.39 14.7 538,981 -0.02 BEARISH
MNS Milnes Holdings 0.12 9.1 1,220,042 -0.03 BEARISH
AFL ASX 50 0.17 6.3 4,079 -0.01 BEARISH
OGC Oceanagold Corporation 3.29 5.4 244,731 -0.29 BEARISH
APX Appen 21.74 5 1,196,976 -0.07 BEARISH
LVH Livehire 0.25 4.2 153,838 -0.02 BEARISH
CUV Clinuvel Pharmaceuticals 31.84 4.1 229,573 -2.13 BEARISH
SXL Southern Cross Media 0.94 3.9 1,455,245 -0.1 BEARISH
MYX Myx 0.56 3.7 4,457,752 -0.01 BEARISH
PME Pro Medicus 25.58 3.6 212,938 -3.47 BEARISH